The transfection technologies market is expected to witness a CAGR of around 8% during the forecast period. Transfection is a modern and powerful method used to insert foreign nucleic acids into eukaryotic cells. The ability to modify host cells’ genetic content enables the broad application of this process in studying normal cellular processes, disease molecular mechanisms, and gene therapeutic effects. Biosimilar drug development is accelerated as several drug patents are anticipated to lapse in the coming years. A combination of cytological, genomic, and proteomic analysis is crucial to their development. As a result, the use of transfection equipment and reagents in proteomic and genomic research has grown. Furthermore, rising cases of cancer & high demand for the synthetic gene will increase the growth of the transfection technologies market.
Request Sample PDF here @ https://univdatos.com/report/transfection-technologies-market/get-a-free-sample-form.php?product_id=35884
For instance, according to the data provided by the International Agency for Research on Cancer (IRAC) in 2018, it is estimated that there will be more than 27.5 million new cancer cases by 2040. Also, the two main purposes of transfection are to produce recombinant proteins or to specifically enhance or inhibit gene expression in transfected cells. As such, transfection is a powerful analytical tool for the study of the function and regulation of genes or gene products, for the production of transgenic organisms, and as a method for gene therapy.
Based on product type, the market is segmented into reagent, instrument, and others. Among them, the reagent category is to witness lucrative growth during the forecast period. This growth can be attributed to factors like advancements in transfection technology, global alliances between leading research institutes to spur drug discovery, rising pharmaceutical and biotechnology companies' R&D spending and research activities, an increase in demand for synthetic genes, and a rise in the prevalence of cancer.
Based on the application, the market is categorized into therapeutic delivery, bio-medical research, protein production, and others. Among these, the therapeutic delivery category is anticipated to register a lucrative CAGR during the forecast period. This is mainly due to the rising demand for precise therapeutic procedures and intensifying research and development activities associated with novel drug and transfection technique discoveries.
Ask for Customization @ https://univdatos.com/report/transfection-technologies-market/get-a-free-sample-form.php?product_id=35884
North America to witness extensive growth
For a better understanding of the market adoption of the transfection technologies market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the presence of cutting-edge research labs and leading pharmaceutical companies that are continuously contributing to research and development. The full-fledged economies of the states in North America force them to spend an incalculable amount of money on developing modern treatments. Additionally, the rising obesity and breast cancer rates in the US are the major contributor to this sector's dominance in the transfection technologies market. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.
According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the Transfection Technologies Market are Lonza Group Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Roche, QIAGEN, Mirus Bio LLC, SignaGen Laboratories, Genlantis Inc., OZ Biosciences, and Promega Corporation.
“Global Transfection Technologies Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.
Get more information , Please Visit us : https://univdatos.com/report/transfection-technologies-market/
Market Segmentation:
- By Product Type (Reagent, Instrument, and Others)
- By Application (Therapeutic Delivery, Bio-Medical Research, Protein Production, and Others)
- By Technology (Physical Transfection, Biochemical-Based Transfection, and Viral-Vector-Based Transfection)
- By End-User (Research Centers and Academic Institutes, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, and Others)
- By Region (North America, Europe, Asia-Pacific, Rest of the World)
- By Company (Lonza Group Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Roche, QIAGEN, Mirus Bio LLC, SignaGen Laboratories, Genlantis Inc., OZ Biosciences, and Promega Corporation)
Key questions answered in the study:
- What are the current and future trends of the global transfection technologies industry?
- How the industry has been evolving in terms of product type, application, technology, and end-user?
- How the competition has been shaping across the countries followed by their comparative factorial indexing?
- What are the key growth drivers and challenges for the global transfection technologies industry?
- What is the customer orientation, purchase behavior, and expectations from the global transfection technologies suppliers across various region and countries?